Category: ~$1.4B

  • Gilead to Acquire MYR for ~$1.4B

    Shots: Gilead to acquire MYR for ~$1.4B in the all-cash transaction along with ~$364.73M as a milestone upon the US FDA’s approval of Hepcludex (bulevirtide) The acquisition will provide Gilead with Hepcludex which has received EMA’s conditional approval for chronic HDV infection in adults with compensated liver disease in Jul’2020. MYR anticipates the submission for […]